Introduction: The phase 3 ALCANZA study showed significant improvements in rate of objective response lasting ≥4 months (ORR4) with BV vs PC of methotrexate (MTX) or bexarotene (Bex) for the treatment of CD30+ CTCL. Here, we examine response according to disease stage and across disease compartments in patients (pts) treated on the ALCANZA study. Methods: Adults with previously treated CD30+ mycosis fungoides (MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL) were randomized to BV 1.8 mg/kg IV, Q3W, for up to 16 three-week cycles, or PC of MTX 5–50 mg PO, QW, or Bex 300 mg/m2 (target dose) PO, QD, for up to 48 weeks. Pts were classified according to baseline Tumor-Node-Metastasis-Blood (TNMB) stage per investigator (INV) as part of global assessment; presence of baseline blood disease was also determined by independent review (IRF). Pts with B2 disease were ineligible. ORR4 was determined by IRF of global response in all compartments using consensus criteria (modified severity weighted assessment tool for skin evaluation by INV, radiographic assessment by IRF, and MF Sézary cell count by IRF). We compared ORR4, ORR, and complete response (CR) rate by disease stage, TNMB stage, and baseline blood disease in the intent-to-treat (ITT) population. Results: The ITT population included 128 pts (97 MF, 31 pcALCL). After a median follow-up of 22.9 months, ORR4 with BV was greater than PC in both MF (50% vs 10%) and pcALCL (75% vs 20%). This was consistent across all MF disease stages; stage IA–IIA, 40% vs 22% (95% CI for rate difference: −16.6%, 49.4%); stage IIB, 63% vs 5% (25.4%, 80.9%); stage IIIA–IIIB, 50% vs 0% (−45.2%, 98.7%); stage IVA, 100% vs 0% (14.9%, 100.0%); and stage IVB, 29% vs not applicable. Table 1 shows response according to baseline clinical and TNMB stage per INV. For MF, ORR4 was 25% (1/4) with BV vs 13% (1/8) with PC for pts with blood involvement (≥B1), and 43% (10/23) with BV vs 12% (3/26) with PC for pts with nodal involvement (≥N1). Out of 35 MF pts with blood disease per IRF (non-B0 blood stage), ORR in the blood compartment was 94% with BV vs 41% with PC; CR rate in the blood compartment was 89% vs 41%. In pcALCL pts, the ORR4 was 89% (8/9) with BV vs 27%% (3/11) with PC in pts with skin-only disease (95% CI for rate difference: 17.9%, 88.3%), and 57% (4/7) with BV vs 0% (0/4) with PC in pts with extracutaneous disease (−9.0%, 93.2%). Conclusions: Significant and durable clinical activity was observed across disease stages and compartments with BV in CTCL pts requiring systemic therapy. Total N (%) ORR4 n (%) ORR n (%) CR n (%) Total N (%) ORR4 n (%) ORR n (%) CR n (%) Keywords: brentuximab vedotin; CD30; cutaneous T-cell lymphoma (CTCL).